Iambic Therapeutics, a Nvidia-backed AI drug discovery startup, surged 16% to $18.50 on its Nasdaq debut on October 15, 2026. The San Diego biotech raised $150 million by selling 9.375 million shares at $16 each. The company’s market value at debut ranged between $758 million and $877 million. The stock experienced a volatility halt before settling into gains. For the period ending June 30, 2026, the company reported a net loss of $94.25 million with collaboration revenue of $18.25 million.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
